Investigational Janus kinase inhibitors

Abstract

Introduction: Dysregulation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is central to the pathophysiology of myeloproliferative neoplasms (MPN). Small molecule inhibitors of JAK family members are currently under investigation for the treatment of MPN. Of these, ruxolitinib has received approval for clinical use in myelofibrosis in the United States and Europe. Areas covered: The clinical results and future development program of major JAK inhibitors, including ruxolitinib, CYT387, SAR302503, lestaurtinib, pacritinib, XL-019, LY2784544, BMS-911453, AZD1480 and NS-018 are reviewed. Expert opinion: JAK inhibitors are effective in relieving organomega..